Trials / Completed
CompletedNCT02650752
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal disease).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lapatinib in Tandem With Capecitabine |
Timeline
- Start date
- 2016-01-06
- Primary completion
- 2021-01-22
- Completion
- 2021-01-22
- First posted
- 2016-01-08
- Last updated
- 2021-01-26
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02650752. Inclusion in this directory is not an endorsement.